Cell Therapeutics, Inc. (CTI) announced it met with the U.S. Food and Drug Administration's Division of Oncology Drug Products (DODP) for re-submitting a New Drug Application (NDA) for pixantrone, for relapsed aggressive non-Hodgkin's lymphoma (NHL) including the potential for accelerated approval based on the PIX301 study results.
The U.S. Department of Health and Human Services (HHS) added eight substances to its carcinogens report, a science-based document that identifies chemicals and biological agents that may put people at an increased risk for cancer.
GlaxoSmithKline and Valeant Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Potiga (ezogabine) tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
Tetragenetics Inc. announced that Marco Cacciuttolo, MD, has been appointed president and chief executive officer and Ben Machielse and Robert Gailus are new to the board of directors. In addition, its headquarters are established in Cambridge, Mass.
Scientists at Harvard University have created a laboratory model using time-lapse video microscopic technology that allows observation of early stages of ovarian cancer metastasis.
Merck reported that patient enrollment in a Phase III clinical study, Centric, has been completed.
A gene linked to emphysema can also be a factor for developing lung cancer, University of Texas, Southwestern Medical Center research indicates.
Knome announced the release of kGAP 2.0, a genome interpretation engine. kGAP 2.0 underlies the genome interpretation and comparison services that Knome provides researchers who seek to make genomic discoveries.
Thermo Fisher Scientific Inc. announced the release of the Accucore HPLC column range, utilizing Core Enhanced Technology to enhance laboratory workflow and efficiency.
ChanTest Corporation has entered into a research collaboration with the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research to improve the prediction of cardiac safety.
A new National Institutes of Health study provides insights about the interaction between a toxic protein called progerin and telomeres, which cap the ends of chromosomes.
Resverlogix Corp. announced that chronic repeated-dose toxicology studies on its lead compound, RVX-208, support the initiation of its longer duration, Phase 2b, clinical trial ASSURE.
The U.S. Food and Drug Administration released draft guidance to provide regulated industries with greater certainty about the use of nanotechnology, which generally involves materials made up of particles that are one billionth of a meter in size.
There is an intimate and complex relationship between inflammation and cancer; and it is well established that tumors secrete many different chemicals that attract host cells which drive inflammation and help to support tumor growth.
A study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration.